A medical device company developing an earlier intervention for cartilage damage and osteoarthritis is raising a $14.2 million round.
Biomimedica Inc. has already secured $11.9 million from 10 investors, according to a U.S. Securities and Exchange Commission filing. CEO Jeff Roberts did not return a call for comment.
The company is developing synthetic cartilage for joint repairs, particularly in osteoarthritis, a degenerative disease of articular cartilage that can lead to the formation of lesions and bone spurs that cause pain in the joints upon weight bearing and movement.
Formed in 2007, the Stanford University spinoff has received past investments from Emergent Medical Partners, Xandex Investments LLC, Asset Management Ventures and Life Science Angels.
By Deanna Pogorelc MedCity News
Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.More posts by Author
- Get Livefyre
- FAQ
